We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.
Chicago, IL and Beloit, WI, June 16, 2020 – Monopar Therapeutics Inc.
March 19, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S.
Highlights include: Company marks reliable U.S. Mo-99 production and supply for customers despite ongoing domestic industry supply shortages FDA approval of RadioGenix System version 1.2
Questions about company, products, supply solutions, careers or anything else?